Influence of IFNγ co-expression on the safety and antiviral efficacy of recombinant fowlpox virus HIV therapeutic vaccines following interruption of antiretroviral therapy

Sean Emery, Anthony D. Kelleher, Cassy Workman, Rebekah L. Puls, Mark Bloch, David Baker, Jonathan Anderson, Jennifer Hoy, Susanna Ip, Kellie Nalliah, Larry D. Ward, Matthew G. Law, David A. Cooper

Research output: Contribution to journalArticleResearchpeer-review

23 Citations (Scopus)

Abstract

Therapeutic immunization to stimulate host immune responses and control human immunodeficiency virus (HIV-1) replication is being investigated as a supplimentary treatment for the management of HIV infection. On completion of an earlier study involving three vaccinations while taking combination antiretroviral therapy (CART), twenty-five subjects with plasma viral load (pVL) <50 copies/mL received a booster vaccination with either placebo (n = 7); fowl pox vaccine (rFPV) expressing HIV-1 Gag/Pol; [partial construct - PC (n = 8)] or rFPV coexpressing HIV-1 Gag/Pol and human interferon-γ [full construct - FC (n = 10)]. One week after the booster vaccination, participants stopped ART and were monitored for safety, pVL and immunological parameters for ≤20 weeks. The time weighted mean change (SD) from baseline plasma HIV RNA was 1.80 (0.72), 1.78 (0.91) and 0.96 (0.91) log10 copies/mL for placebo, PC and FC recipients respectively (p = 0.06; mean differences between placebo and FC). Laboratory evaluations did not reveal differences in anti-HIV specific immune responses between study arms. No difference between treatment arms for host genetic factors known to affect pVL was demonstrated. In conclusion, vaccination with FC was associated with a trend toward lower rates of HIV replication following cessation of ART relative to placebo or PC. The promising antiretrovirological effect supports further study of FC in a larger trial with a broader population of patients with HIV disease.

Original languageEnglish
Pages (from-to)260-267
Number of pages8
JournalHuman Vaccines
Volume3
Issue number6
DOIs
Publication statusPublished - 1 Jan 2007

Keywords

  • HIV
  • Pox virus vector vaccine
  • Therapeutic vaccine

Cite this

Emery, Sean ; Kelleher, Anthony D. ; Workman, Cassy ; Puls, Rebekah L. ; Bloch, Mark ; Baker, David ; Anderson, Jonathan ; Hoy, Jennifer ; Ip, Susanna ; Nalliah, Kellie ; Ward, Larry D. ; Law, Matthew G. ; Cooper, David A. / Influence of IFNγ co-expression on the safety and antiviral efficacy of recombinant fowlpox virus HIV therapeutic vaccines following interruption of antiretroviral therapy. In: Human Vaccines. 2007 ; Vol. 3, No. 6. pp. 260-267.
@article{0fe40c7c900b482ead591258dd3f61f7,
title = "Influence of IFNγ co-expression on the safety and antiviral efficacy of recombinant fowlpox virus HIV therapeutic vaccines following interruption of antiretroviral therapy",
abstract = "Therapeutic immunization to stimulate host immune responses and control human immunodeficiency virus (HIV-1) replication is being investigated as a supplimentary treatment for the management of HIV infection. On completion of an earlier study involving three vaccinations while taking combination antiretroviral therapy (CART), twenty-five subjects with plasma viral load (pVL) <50 copies/mL received a booster vaccination with either placebo (n = 7); fowl pox vaccine (rFPV) expressing HIV-1 Gag/Pol; [partial construct - PC (n = 8)] or rFPV coexpressing HIV-1 Gag/Pol and human interferon-γ [full construct - FC (n = 10)]. One week after the booster vaccination, participants stopped ART and were monitored for safety, pVL and immunological parameters for ≤20 weeks. The time weighted mean change (SD) from baseline plasma HIV RNA was 1.80 (0.72), 1.78 (0.91) and 0.96 (0.91) log10 copies/mL for placebo, PC and FC recipients respectively (p = 0.06; mean differences between placebo and FC). Laboratory evaluations did not reveal differences in anti-HIV specific immune responses between study arms. No difference between treatment arms for host genetic factors known to affect pVL was demonstrated. In conclusion, vaccination with FC was associated with a trend toward lower rates of HIV replication following cessation of ART relative to placebo or PC. The promising antiretrovirological effect supports further study of FC in a larger trial with a broader population of patients with HIV disease.",
keywords = "HIV, Pox virus vector vaccine, Therapeutic vaccine",
author = "Sean Emery and Kelleher, {Anthony D.} and Cassy Workman and Puls, {Rebekah L.} and Mark Bloch and David Baker and Jonathan Anderson and Jennifer Hoy and Susanna Ip and Kellie Nalliah and Ward, {Larry D.} and Law, {Matthew G.} and Cooper, {David A.}",
year = "2007",
month = "1",
day = "1",
doi = "10.4161/hv.4627",
language = "English",
volume = "3",
pages = "260--267",
journal = "Human Vaccines & Immunotherapeutics",
issn = "2164-5515",
publisher = "Taylor & Francis",
number = "6",

}

Emery, S, Kelleher, AD, Workman, C, Puls, RL, Bloch, M, Baker, D, Anderson, J, Hoy, J, Ip, S, Nalliah, K, Ward, LD, Law, MG & Cooper, DA 2007, 'Influence of IFNγ co-expression on the safety and antiviral efficacy of recombinant fowlpox virus HIV therapeutic vaccines following interruption of antiretroviral therapy', Human Vaccines, vol. 3, no. 6, pp. 260-267. https://doi.org/10.4161/hv.4627

Influence of IFNγ co-expression on the safety and antiviral efficacy of recombinant fowlpox virus HIV therapeutic vaccines following interruption of antiretroviral therapy. / Emery, Sean; Kelleher, Anthony D.; Workman, Cassy; Puls, Rebekah L.; Bloch, Mark; Baker, David; Anderson, Jonathan; Hoy, Jennifer; Ip, Susanna; Nalliah, Kellie; Ward, Larry D.; Law, Matthew G.; Cooper, David A.

In: Human Vaccines, Vol. 3, No. 6, 01.01.2007, p. 260-267.

Research output: Contribution to journalArticleResearchpeer-review

TY - JOUR

T1 - Influence of IFNγ co-expression on the safety and antiviral efficacy of recombinant fowlpox virus HIV therapeutic vaccines following interruption of antiretroviral therapy

AU - Emery, Sean

AU - Kelleher, Anthony D.

AU - Workman, Cassy

AU - Puls, Rebekah L.

AU - Bloch, Mark

AU - Baker, David

AU - Anderson, Jonathan

AU - Hoy, Jennifer

AU - Ip, Susanna

AU - Nalliah, Kellie

AU - Ward, Larry D.

AU - Law, Matthew G.

AU - Cooper, David A.

PY - 2007/1/1

Y1 - 2007/1/1

N2 - Therapeutic immunization to stimulate host immune responses and control human immunodeficiency virus (HIV-1) replication is being investigated as a supplimentary treatment for the management of HIV infection. On completion of an earlier study involving three vaccinations while taking combination antiretroviral therapy (CART), twenty-five subjects with plasma viral load (pVL) <50 copies/mL received a booster vaccination with either placebo (n = 7); fowl pox vaccine (rFPV) expressing HIV-1 Gag/Pol; [partial construct - PC (n = 8)] or rFPV coexpressing HIV-1 Gag/Pol and human interferon-γ [full construct - FC (n = 10)]. One week after the booster vaccination, participants stopped ART and were monitored for safety, pVL and immunological parameters for ≤20 weeks. The time weighted mean change (SD) from baseline plasma HIV RNA was 1.80 (0.72), 1.78 (0.91) and 0.96 (0.91) log10 copies/mL for placebo, PC and FC recipients respectively (p = 0.06; mean differences between placebo and FC). Laboratory evaluations did not reveal differences in anti-HIV specific immune responses between study arms. No difference between treatment arms for host genetic factors known to affect pVL was demonstrated. In conclusion, vaccination with FC was associated with a trend toward lower rates of HIV replication following cessation of ART relative to placebo or PC. The promising antiretrovirological effect supports further study of FC in a larger trial with a broader population of patients with HIV disease.

AB - Therapeutic immunization to stimulate host immune responses and control human immunodeficiency virus (HIV-1) replication is being investigated as a supplimentary treatment for the management of HIV infection. On completion of an earlier study involving three vaccinations while taking combination antiretroviral therapy (CART), twenty-five subjects with plasma viral load (pVL) <50 copies/mL received a booster vaccination with either placebo (n = 7); fowl pox vaccine (rFPV) expressing HIV-1 Gag/Pol; [partial construct - PC (n = 8)] or rFPV coexpressing HIV-1 Gag/Pol and human interferon-γ [full construct - FC (n = 10)]. One week after the booster vaccination, participants stopped ART and were monitored for safety, pVL and immunological parameters for ≤20 weeks. The time weighted mean change (SD) from baseline plasma HIV RNA was 1.80 (0.72), 1.78 (0.91) and 0.96 (0.91) log10 copies/mL for placebo, PC and FC recipients respectively (p = 0.06; mean differences between placebo and FC). Laboratory evaluations did not reveal differences in anti-HIV specific immune responses between study arms. No difference between treatment arms for host genetic factors known to affect pVL was demonstrated. In conclusion, vaccination with FC was associated with a trend toward lower rates of HIV replication following cessation of ART relative to placebo or PC. The promising antiretrovirological effect supports further study of FC in a larger trial with a broader population of patients with HIV disease.

KW - HIV

KW - Pox virus vector vaccine

KW - Therapeutic vaccine

UR - http://www.scopus.com/inward/record.url?scp=37649006663&partnerID=8YFLogxK

U2 - 10.4161/hv.4627

DO - 10.4161/hv.4627

M3 - Article

VL - 3

SP - 260

EP - 267

JO - Human Vaccines & Immunotherapeutics

JF - Human Vaccines & Immunotherapeutics

SN - 2164-5515

IS - 6

ER -